Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6

Abstract

Precise and efficient manipulation of genes is crucial for understanding the molecular mechanisms that govern human hematopoiesis and for developing novel therapies for diseases of the blood and immune system. Current methods do not enable precise engineering of complex genotypes that can be easily tracked in a mixed population of cells. We describe a method to multiplex homologous recombination (HR) in human hematopoietic stem and progenitor cells and primary human T cells by combining rAAV6 donor delivery and the CRISPR/Cas9 system delivered as ribonucleoproteins (RNPs). In addition, the use of reporter genes allows FACS-purification and tracking of cells that have had multiple alleles or loci modified by HR. We believe this method will enable broad applications not only to the study of human hematopoietic gene function and networks, but also to perform sophisticated synthetic biology to develop innovative engineered stem cell-based therapeutics.

Article and author information

Author details

  1. Rasmus O Bak

    Department of Pediatrics, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7383-0297
  2. Daniel P Dever

    Department of Pediatrics, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.
  3. Andreas Reinisch

    Department of Medicine, Division of Hematology, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.
  4. David Cruz Hernandez

    Department of Medicine, Division of Hematology, Stanford University, Stanford, United States
    Competing interests
    No competing interests declared.
  5. Ravindra Majeti

    Department of Medicine, Division of Hematology, Stanford University, Stanford, United States
    For correspondence
    rmajeti@stanford.edu
    Competing interests
    Ravindra Majeti, has equity and consults for Forty Seven Inc..
  6. Matthew H Porteus

    Department of Pediatrics, Stanford University, Stanford, United States
    For correspondence
    mporteus@stanford.edu
    Competing interests
    Matthew H Porteus, has equity and consults for CRISPR Therapeutics..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3850-4648

Funding

Danish Council for Independent Research (DFF-1333-00106B)

  • Rasmus O Bak

Danish Council for Independent Research (DFF-1331-00735B)

  • Rasmus O Bak

National Institutes of Health (R01- AI097320)

  • Matthew H Porteus

National Institutes of Health (R01-AI120766)

  • Matthew H Porteus

Stanford Child Health Research Institute (Postdoctoral Award)

  • Daniel P Dever

Austrian Research Council (Erwin Schroedinger Postdoctoral Fellowship)

  • Andreas Reinisch

Amon G. Carter Foundation

  • Matthew H Porteus

Laurie Kraus Lacob Faculty Scholar Award in Pediatric Translational Research (Scholar Award)

  • Matthew H Porteus

National Institutes of Health (PN2EY018244)

  • Matthew H Porteus

Stanford Ludwig Center for Cancer Stem Cell Research

  • Ravindra Majeti

National Institutes of Health (R01-CA188055)

  • Ravindra Majeti

New York Stem Cell Foundation (Robertson Investigator)

  • Ravindra Majeti

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Animal experiments were performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The experimental protocol was approved by Stanford University's Administrative Panel on Lab Animal Care (IACUC 25065).

Copyright

© 2017, Bak et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 8,627
    views
  • 1,755
    downloads
  • 97
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Rasmus O Bak
  2. Daniel P Dever
  3. Andreas Reinisch
  4. David Cruz Hernandez
  5. Ravindra Majeti
  6. Matthew H Porteus
(2017)
Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6
eLife 6:e27873.
https://doi.org/10.7554/eLife.27873

Share this article

https://doi.org/10.7554/eLife.27873

Further reading

    1. Stem Cells and Regenerative Medicine
    Sujeethkumar Prithiviraj, Alejandro Garcia Garcia ... Paul E Bourgine
    Research Article

    Tissue engineering strategies predominantly rely on the production of living substitutes, whereby implanted cells actively participate in the regenerative process. Beyond cost and delayed graft availability, the patient-specific performance of engineered tissues poses serious concerns on their clinical translation ability. A more exciting paradigm consists in exploiting cell-laid, engineered extracellular matrices (eECMs), which can be used as off-the-shelf materials. Here, the regenerative capacity solely relies on the preservation of the eECM structure and embedded signals to instruct an endogenous repair. We recently described the possibility to exploit custom human stem cell lines for eECM manufacturing. In addition to the conferred standardization, the availability of such cell lines opened avenues for the design of tailored eECMs by applying dedicated genetic tools. In this study, we demonstrated the exploitation of CRISPR/Cas9 as a high precision system for editing the composition and function of eECMs. Human mesenchymal stromal/stem cell (hMSC) lines were modified to knock out vascular endothelial growth factor (VEGF) and Runt-related transcription factor 2 (RUNX2) and assessed for their capacity to generate osteoinductive cartilage matrices. We report the successful editing of hMSCs, subsequently leading to targeted VEGF and RUNX2-knockout cartilage eECMs. Despite the absence of VEGF, eECMs retained full capacity to instruct ectopic endochondral ossification. Conversely, RUNX2-edited eECMs exhibited impaired hypertrophy, reduced ectopic ossification, and superior cartilage repair in a rat osteochondral defect. In summary, our approach can be harnessed to identify the necessary eECM factors driving endogenous repair. Our work paves the road toward the compositional eECMs editing and their exploitation in broad regenerative contexts.